Treatment of hereditary angioedema with plasma-derived C1 inhibitor

Therapeutics and Clinical Risk Management

Volumn 4, Issue 5, 2008, Pages 975-982

  Prematta, Michael J ^a   Prematta, Tracy ^a   Craig, Timothy J ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

C1 esterase inhibitor; C1 inhibitor; Hereditary angioedema; Hereditary angioedema treatment

Indexed keywords

BERINERT P; CINRYZE; COMPLEMENT COMPONENT C1S INHIBITOR; ECALLANTIDE; ICATIBANT; PLACEBO; RHUCIN; UNCLASSIFIED DRUG;

ANGIONEUROTIC EDEMA; BODY TEMPERATURE DISORDER; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIZZINESS; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DYSPNEA; FACE REDNESS; FAINTNESS; FEVER; HUMAN; NAUSEA; OUTCOME ASSESSMENT; PARESTHESIA; REVIEW; SKIN REDNESS; TASTE DISORDER; TREATMENT DURATION; TREATMENT RESPONSE; VERTIGO; VIRUS TRANSMISSION;

EID: 56749136179     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Bernstein JA. 2008. Hereditary angioedema: a cunent state-of-the-art review, VIII: current status of emerging therapies. Ann Allergy Asthma Immunol, 100:S41-S6.
2. Bernstein JA, Levy R, Wasserman RL, et al. 2008. Treatment of acute abdominal and facial attacks of hereditary angioedema (HAE) with human C1 esterase inhibitor (C1-INH): results of a global, multicenter, randomized, placebo-controlled, phase I/II Study (I.M.P.A.C.T.1) [abstract]. J Allergy Clin Immunol, 121:795.
3. Bork K, Barnstedt S-E. 2001. Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema. Arch Intern Med, 161:714-18.
4. Bork K, Frank J, Grundt B, et al. 2007. Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). J Allergy Clin Immunol, 119:1497-503.
5. Bork K, Meng G, Staubach P, et al. 2005. Treatment with C1-inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema. Transfusion, 45:1774-84.
6. Choi G, Soeters MR, Farkas H, et al. 2007. Recombinant human C1-inhibitor in the treatment of acute angioedema attacks. Transfusion, 47:1028-32.
7. Cicardi M, Mannucci PM, Castelli R, et al. 1995. Reduction in transmission of hepatitis C after the introduction of a heat-treatment step in the production of C1-inhibitor concentrate. Transfusion, 35:209-12.
8. Craig TJ, Wassermann RL, Levy R, et al. 2008; C1-esterase inhibitor (C1-INH) - standard of care for the treatment of acute attacks in hereditary angioedema (HAE): Initial results of an ongoing, prospective, open-label study in North America (I.M.P.A.C.T. 2) (Abstract Only). J Allergy Clin Immunol, 121:S98-9.
9. Farkas H, Jakab L, Temesszentandrasi G, et al. 2007. Hereditary angioedema: a decade of human C1-inhibitor concentrate therapy. J Allergy Clin Immunol, 120:941-7.
10. Frank MM, Gelfand JA, Atkinson JP. 1976. Hereditary angioedema: the clinical syndrome and its management. Ann Intern Med, 84:580-93.
11. Gadek JE, Hosea SW, Gelfand JA, et al. 1980. Replacement therapy in hereditary angioedema: successful treatment of acute episodes of angioedema with partly purified C1 inhibitor. New Engl J Med, 302:542-6.
12. Gompels MM, Lock RJ, Abinum M, et al. C1 inhibitor deficiency: consensus document. Clin Exp Immunol, 139:379-94.
13. Hosea SW, Santaella ML, Brown EJ, et al. 1980. Long-term therapy of hereditary angioedema with danazol. Ann Intern Med, 93:809-12.
14. Juers M, Groner A. Virus safety of current plasma derived C1-INH: The Aventis Behring experience. J Allergy Clin Immunol, 114:S96-S8.
15. Kunschak M, Engl W, Maritsch F, et al. 1998. A randomized, controlled trial to study the efficacy and safety of C1 inhibitor concentrate in treating hereditary angioedema. Transfusion, 38:540-9.
16. Levi M, Choi G, Picavet C, et al. 2006. Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency. J Allergy Clin Immunol, 117:904-8.
17. Longhurst HJ, Carr S, Khair K. 2007. C1-inhibitor concentrate home therapy for hereditary angioedema: a viable, effective treatment option. Clin Exp Immunol, 147:11-7.
18. Ohela K, Rasanen JA, Wagner O. 1973. Hereditary angio-neurotic oedema - genealogical and immunological studies. Ann Clin Res, 5:174-80.
19. Pickering RJ, Kelly JR, Good RA, et al. 1969. Replacement therapy in hereditary angioedema - successful treatment of two patients with fresh frozen plasma. Lancet, 1:326-30.
20. Prematta M, Gibbs JG, Pratt EL, et al. 2007. Fresh frozen plasma for the treatment of hereditary angioedema. Ann Allergy Asthma Immuol, 98:383-8.
21. Rais M, Unzeitig J, Grant JA. 1999. Refractory exacerbations of hereditary angioedema with associated Helicobacter pylori infection. J Allergy Clin Immunol, 103:713-4.
22. Rosen FS, Austen KF. 1969. The neurotic edema. N Engl J Med, 280:1356-7.
23. Schneider L, Lumry W, Vegh A, et al. 2007. Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor. J Allergy Clin Immunol, 120:416-22.
24. Terpstra FG, Kleijn M, Koenderman AH, et al. 2007. Viral safety of C1-inhibitor NF. Biologicals, 35:173-81.
25. van Doorn MB, Burggraaf J, van Dam T, et al. 2005. A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema. J Allergy Clin Immuol, 116:876-83.
26. Visy B, Fust G, Bygum A, et al. 2007. Helicobacter pylori infection as a trigger factor of attacks in patients with hereditary angioedema. Helicobacter, 12:251-7.
27. Waytes AT, Rosen FS, Frank MM. 1996. Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. N Engl J Med, 334:1630-4.
28. Zuraw B, Busse P, White M, et al. 2008. Efficacy and safety of long-term prophylaxis with C1-Inhibitor (C1INH) concentrate in patients with hereditary angioedema (HAE). AAAAI Poster Presentation. March 2008. Philadelphia, PA.
29. Zuraw BL, Schaefer O, Grant JA, et al. 2007. Results of a randomized double-blind controlled study of nanofiltered C1-inhibitor for the treatment of HAE attacks. ACAAI Poster Presentation, 9 Nov 2007. Dallas, TX.